A Study of the Safety and Tolerability of V419 in Healthy Infants at 2,4, 6 and 12 to 14 Months of Age
Phase of Trial: Phase II
Latest Information Update: 01 Oct 2008
At a glance
- Drugs Hib-DTaP-hepatitis B-poliovirus vaccine (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- 01 Oct 2008 Official title amended as reported by ClinicalTrials.gov.
- 01 Oct 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Oct 2008 Trial identifier added as V419-003 as reported by ClinicalTrials.gov.